6 结果
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of R-(-)-gossypol acetic acid (AT-101) that can be combined with lenalidomide and dexamethasone in patients with relapsed symptomatic multiple myeloma (MM). (Phase I) II. To determine the overall response rate (partial response or
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of lenalidomide in combination with AT-101 (R-(-)-gossypol acetic acid). (Phase I) II. To assess the overall response rate of lenalidomide in combination with AT-101. (Phase II)
SECONDARY OBJECTIVES:
I. To assess the overall
PRIMARY OBJECTIVES:
I. The primary end point will be to determine the maximum tolerated dose of AT-101 with paclitaxel and carboplatin.
SECONDARY OBJECTIVES:
I. To describe the toxicities associated with the combination of paclitaxel, carboplatin, and AT-101.
II. To evaluate the human
PRIMARY OBJECTIVE:
I. To determine the proportion of patients with recurrent, metastatic, or primary unresectable adrenocortical carcinoma who achieve an objective response to R-(-)-gossypol acetic acid.
SECONDARY OBJECTIVES::
I. To evaluate the safety of this drug in these patients. II. To
PRIMARY OBJECTIVES:
I. To determine the objective response rate of R-(-)-gossypol in patients with recurrent chemotherapy-sensitive extensive stage small cell lung cancer.
II. To determine the time to disease progression. III. To determine the overall survival. IV. To assess the toxicities
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of AT-101 (R-(-)-gossypol) when combined with cisplatin and etoposide in patients with advanced, refractory solid tumors and/or extensive stage small cell lung cancer (ES-SCLC). In addition, to